Effectiveness of empiric aztreonam compared to other beta-lactams for treatment of *Pseudomonas aeruginosa* infections

Michael Hogan¹
Mary Barna Bridgeman¹
Gee Hee Min¹
Deepali Dixit¹
Patrick J Bridgeman¹
Navaneeth Narayanan¹,²

¹Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA; ²Division of Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

**Purpose:** To evaluate the use of aztreonam as an active empiric therapy against subsequent culture of *Pseudomonas aeruginosa* (*P. aeruginosa*).

**Methods:** This was a retrospective cohort study conducted among patients who received either aztreonam or an antipseudomonal beta-lactam (BL) as an empiric therapy with subsequent culture of *P. aeruginosa*. All patients with at least one positive culture for *P. aeruginosa* between January 2014 and August 2016 were included in this analysis. The primary composite outcome was empiric therapy failure, defined as inappropriate empiric therapy, alteration of empiric antibiotic following culture results, or 30-day in-hospital mortality. Secondary outcomes included appropriate empiric therapy, alteration of empiric therapy, 30-day-in-hospital mortality, and post-culture hospital length of stay.

**Results:** The primary outcome of empiric therapy failure was significantly higher in the aztreonam group than in the BL group (77.8% vs 41.9%; *P* = 0.004). The aztreonam group had a lower rate of appropriate empiric therapy compared with the BL group (44.4% vs 66.1%; *P* = 0.074) and higher alteration of empiric therapy once susceptibilities were known than when compared with the BL group (61.1% vs 28.2%; *P* = 0.005). Although numerically higher, 30-day-in-hospital mortality and median hospital length of stay were not significantly different between the two groups.

**Conclusion:** Empiric therapy failure occurred more often when initially using aztreonam vs a BL in a patient who subsequently had a *P. aeruginosa* infection. Only a third of patients within the aztreonam group had a documented BL allergy, demonstrating an inclination for clinicians to utilize this drug as an empiric therapy when there were more appropriate therapies available.

**Keywords:** *Pseudomonas aeruginosa*, aztreonam, empiric therapy, anti-bacterial agents, beta-lactams

**Introduction**

*Pseudomonas aeruginosa* (*P. aeruginosa*) is a multi-drug resistant (MDR), aerobic, gram-negative bacillus bacteria. Infections caused by *P. aeruginosa* attribute to 10%–15% of hospital-acquired infections around the world,¹ and ~7% of infections in the United States.² Although adequate treatment regimens are available to treat *P. aeruginosa*, these infections contribute to high morbidity and mortality rates.³ Mortality due to *P. aeruginosa* infections may be attributed to the high virulence of *P. aeruginosa*, increased resistance to many antimicrobials favoring inadequacy of empiric therapy, and its ability to develop resistance during therapy; patients with prolonged hospitalizations are highly susceptible to nosocomial infections due to certain comorbidities, such as immunosuppression.⁴-⁶ *P. aeruginosa* develops resistance through intrinsic structural
Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 11-Jan-2019
For personal use only.

The purpose of this study was to assess clinical outcomes of patients who receive aztreonam as an empiric therapy for the intended treatment of *P. aeruginosa* infections compared with traditional antipseudomonal BL empiric therapy.

**Methods**

**Setting and study population**

We conducted a retrospective cohort study of all inpatients admitted from January 2014 to August 2016 at a tertiary care academic medical center. Patients >18 years old with at least one positive culture for *P. aeruginosa* who were treated as such with either aztreonam or other antipseudomonal BL therapy (ceftazidime, ceftolozane/tazobactam, cefepime, piperacillin/tazobactam, meropenem, imipenem, and doripenem) as empiric monotherapy to treat *P. aeruginosa* for ≥48 hours were included. Patients were identified through the hospital microbiology laboratory database, and further clinical data were abstracted from the hospital electronic medical record (EMR). Only the first infection/treatment episode per patient was recorded and analyzed by assessing the first sample for patients with more than one positive culture who were >18 years old with at least one positive culture for *P. aeruginosa* who were treated as such with either aztreonam or other antipseudomonal BL therapy (ceftazidime, ceftolozane/tazobactam, cefepime, piperacillin/tazobactam, meropenem, imipenem, and doripenem) as empiric monotherapy to treat *P. aeruginosa* for ≥48 hours were included. Patients were excluded if they were being treated with a FQ or NBL therapy, were on dual therapy, and were only prescribed targeted therapy after culture susceptibility results known, were pregnant, or were treated as outpatients. The Rutgers University Institutional Review Board approved this study and determined patient consent for medical record review was not required based on the retrospective nature of this study; deidentified patient data were collected and analyzed.

**Predictor and covariates**

The primary predictor of interest was the use of empiric aztreonam therapy with a control comparison of other BLs with antipseudomonal activity. Data on multiple demographic and clinical covariates were collected including age, sex,
weight, severity of illness (measured by Sequential Organ Failure Assessment Score [SOFA] score), comorbidities (measured by Charlson Comorbidity index), presence of documented BL allergy, and source of culture positive for *P. aeruginosa*. Empiric therapy was confirmed by reviewing the EMR and assessing when the positive *P. aeruginosa* culture was collected and time until first dose administration of either aztreonam or a BL.

**Outcomes measures**

The primary composite outcome was empiric therapy failure, defined as inappropriate empiric therapy, alteration of empiric antibiotic following culture results, or 30-day in-hospital mortality. Secondary outcomes included appropriate empiric therapy, defined as receipt of an antibiotic with in-vitro coverage of the cultured pathogen (*P. aeruginosa*) prior to culture/sensitivity results, alteration of empiric therapy, defined as change of antibiotic therapy following culture results, 30-day in-hospital mortality, and post-culture hospital length of stay (LOS).

**Statistical analysis**

Descriptive statistics were utilized to describe all variables. Continuous data were reported as the median and interquartile range (IQR). All categorical variables were reported as percentages. The Mann–Whitney U-test was used to test for comparison of nonparametric continuous variables. The chi-square test was used for comparison of categorical variables. A two-sided significance level of *P*<0.05 was set a priori.

The primary relationship of interest is the association of empiric aztreonam therapy and empiric therapy failure. We performed a bivariate logistic regression analysis on measured covariates to assess for possible confounders. Any variable in the bivariate analysis with *P*<0.2 and deemed clinically relevant was entered into a multivariate logistic regression model to adjust for potential confounding effects. An adjusted OR (aOR) and 95% CI were calculated to determine the magnitude of association of empiric aztreonam and empiric therapy failure while controlling for confounders. Data analysis was performed using Stata, version 15.0 (StataCorp).

**Results**

**Patient population**

During the study period, 636 positive cultures of *P. aeruginosa* were screened for eligibility. A total of 142 patients met the inclusion criteria with 18 (12.7%) patients in the aztreonam group and 124 (87.3%) patients in the BL group. Majority of patients excluded were those who received only targeted antibiotic therapy based on culture results, not empiric therapy, followed by patients who were not prescribed any antimicrobial treatment for a positive culture. Most patients in the control group were ordered to receive empiric piperacillin–tazobactam therapy (98/124).

Baseline characteristics between groups were similar (Table 1). The median age of patients was 72.5 years (IQR, 64.9–83.5 years) in the aztreonam group and 67.4 years (IQR, 55.3–76.4 years) in the BL group (*P*=0.026). The majority of patients in each group were male (61.1% vs 58.9%; *P*=0.857). Source of infections were similar between groups, with respiratory and urine sources making up more than half of patients.

Patients were more severely ill in the aztreonam group than in the BL group according to SOFA scores, with a median score of 9.5 (IQR, 4–14) in the aztreonam group and

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Other Anti-PsA BL (n=124)</th>
<th>Aztreonam (n=18)</th>
<th><em>P</em>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (IQR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>67.4 (55.3–76.4)</td>
<td>72.5 (64.9–83.5)</td>
<td></td>
<td>0.026</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>73 (58.9)</td>
<td>11 (61.1)</td>
<td>0.857</td>
</tr>
<tr>
<td>Weight (kg), median (IQR)</td>
<td>73.3 (62.8–89.3)</td>
<td>76.7 (70.3–94.1)</td>
<td>0.265</td>
</tr>
<tr>
<td>SOFA score, median (IQR)</td>
<td>6.5 (3–11)</td>
<td>9.5 (4–14)</td>
<td>0.216</td>
</tr>
<tr>
<td>Charlson Comorbidity Index, median (IQR)</td>
<td>7 (4–10)</td>
<td>8 (7–10)</td>
<td>0.117</td>
</tr>
<tr>
<td>Documented beta-lactam allergy, n (%)</td>
<td>4 (3.2)</td>
<td>7 (38.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Source of culture, n (%)</td>
<td></td>
<td></td>
<td>0.151</td>
</tr>
<tr>
<td>Blood</td>
<td>13 (10.5)</td>
<td>1 (5.6)</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>52 (41.9)</td>
<td>7 (38.9)</td>
<td></td>
</tr>
<tr>
<td>Urine</td>
<td>27 (21.8)</td>
<td>4 (22.2)</td>
<td></td>
</tr>
<tr>
<td>Tissue/wound</td>
<td>21 (16.9)</td>
<td>1 (5.6)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>11 (8.9)</td>
<td>5 (27.8)</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Other Anti-PsA BL includes piperacillin–tazobactam (n=98), meropenem (n=15), ceftazidime (n=8), and cefepime (n=3).

**Abbreviations:** Anti-PsA BL, anti-pseudomonal beta-lactam; IQR, interquartile range; SOFA, sequential organ failure assessment.
6.5 (IQR, 3–11) in the BL group (\(P=0.216\)). A significantly higher number of patients had documented BL allergy in the aztreonam group than in the BL group (38.9% vs 3.2%; \(P<0.001\)).

**Outcomes**

The primary outcome of empiric therapy failure was significantly higher in the aztreonam group than in the BL group (77.8% vs 41.9%; \(P=0.004\); Table 2). The aztreonam group had a lower rate of appropriate empiric therapy (44.4%) compared with the BL group (66.1%, \(P=0.074\) and significantly higher alteration of empiric therapy (61.1%) compared with the BL group (28.2%, \(P=0.005\)). Although numerically higher, 30-day in-hospital mortality and median post-culture draw hospital LOS were not statistically significantly different between the two groups. In multivariate logistic regression analysis, the odds of empiric therapy failure were significantly higher among patients who received aztreonam as an empiric therapy when compared with those who received other BL therapy (aOR 6.15; 95% CI 1.56, 24.33) after adjusting for SOFA score and source of positive *P. aeruginosa* culture (Table 3).

**Discussion**

This study was conducted with the intent of assessing the effectiveness of empiric aztreonam therapy for patients with subsequent cultures identifying *P. aeruginosa* when compared with standard antipseudomonal BL therapy. Of note, investigators observed patients receiving empiric aztreonam to be generally older with higher severity of illness, according to SOFA scores; we hypothesize this because aztreonam is generally a more conservative selection in patients with even a remote history of penicillin allergy. We observed that those patients receiving empiric aztreonam had a significantly higher rate of empiric therapy failure compared with use of other therapies. After adjusting for confounding factors, aztreonam remained significantly associated with empiric therapy failure, with higher odds when compared with standard antipseudomonal BL empiric therapy. The primary composite outcome findings are driven by the significantly higher rate of alteration of empiric therapy by the treating clinician following culture and sensitivity results and numerically higher inappropriate therapy and in-hospital mortality.

In addition to the main findings, it is important to note that <40% of patients treated empirically with aztreonam had documented BL allergies, suggesting that another more effective antipseudomonal BL could have been used, although improper allergy documentation limits definitive conclusions regarding the use of first-line therapy.

National guidelines from the IDSA cautiously recommend empiric aztreonam as an initial therapy for a patient with suspected *P. aeruginosa* infection.\(^{11}\) We have observed clinicians at our institution prescribing aztreonam monotherapy as an empiric therapy to cover for gram-negative pathogens; however, based on our study results, we observed a high likelihood of empiric therapy failure when cultures grow *P. aeruginosa*.

There are limited data available on the use of aztreonam as an empiric therapy to cover *P. aeruginosa*. One study, conducted in 1993, compared empiric aztreonam to

<table>
<thead>
<tr>
<th>Study outcome</th>
<th>Other Anti-PsA BL (n=124)</th>
<th>Aztreonam (n=18)</th>
<th>(P)-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Empiric therapy failure, n (%)</td>
<td>52 (41.9)</td>
<td>14 (77.8)</td>
<td>0.004</td>
</tr>
<tr>
<td>Alteration of empiric therapy, n (%)</td>
<td>35 (28.2)</td>
<td>11 (61.1)</td>
<td>0.005</td>
</tr>
<tr>
<td>Appropriate empiric therapy, n (%)</td>
<td>82 (66.1)</td>
<td>8 (44.4)</td>
<td>0.074</td>
</tr>
<tr>
<td>Thirty-day in-hospital mortality, n (%)</td>
<td>8 (6.5)</td>
<td>3 (16.7)</td>
<td>0.13</td>
</tr>
<tr>
<td>Post-culture draw hospital LOS, median (IQR)</td>
<td>13 (7–21.5)</td>
<td>13.5 (10–27)</td>
<td>0.229</td>
</tr>
</tbody>
</table>

**Notes:** Other Anti-PsA BL includes piperacillin–tazobactam (n=98), meropenem (n=15), ceftazidime (n=8), and cefepime (n=3).

**Abbreviations:** Anti-PsA BL, anti-pseudomonal beta-lactam; IQR, interquartile range; LOS, length of stay.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Unadjusted analysis</th>
<th>Multivariable analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Crude OR (95% CI)</td>
<td>Adjusted OR (95% CI)</td>
</tr>
<tr>
<td>Empiric aztreonam therapy</td>
<td>4.85 (1.51, 15.57)</td>
<td>6.15 (1.56, 24.33)</td>
</tr>
<tr>
<td>Other Anti-PsA BL therapy</td>
<td>Reference</td>
<td>Reference</td>
</tr>
</tbody>
</table>

**Note:** Adjusted for SOFA score and source of positive *Pseudomonas aeruginosa* culture.

**Abbreviations:** Anti-PsA BL, anti-pseudomonal beta-lactam; SOFA, sequential organ failure assessment.
aminoglycoside therapy in the treatment of serious lower respiratory infections; most bacteria isolated in this study were *Enterobacteriaceae* sp. (44%), with 19% of patients found to have *P. aeruginosa* infections. Overall, positive results came from this study, with 72% eradication from the aztreonam group vs 57% from the control group ($P=0.357$) with shorter hospital stays in the aztreonam group. This study was conducted closer to aztreonam’s FDA approval date (1986), with less bacterial exposure than it has now to *P. aeruginosa*, so resistance patterns cannot be extrapolated. This study also shows the value that, although similar in efficacy to aminoglycosides, aztreonam was better tolerated with favorable safety data.

There are conflicting mortality results when evaluating inappropriate initial empiric antibiotic selection. Patients who are undoubtedly sicker, including those on ventilators, and those with sepsis, showed increased mortality when inappropriate empiric therapy was utilized. Other studies found no significance in mortality risk when looking at inappropriate empiric therapy for gram-positive and gram-negative organisms. One study had similar results to our study when looking at inappropriate empiric therapy with regard to *P. aeruginosa*. Investigators found, in general, that inappropriate empiric therapy did not lead to higher mortality; however, when evaluated according to specific sites of infection, there was an association with respiratory and intraabdominal infections cultured with *P. aeruginosa* and mortality.

In our study, we see only one-third of patients with reported BL allergies were treated with aztreonam. A study with a similar study design as ours retrospectively evaluated patients with severe BL allergies receiving either a BL or an NBL (including aztreonam). They found that, despite a slight risk of hypersensitivity reactions occurring with the use of a BL in documented BL-allergic patients, there was a significant reduction in clinical failure at 72–96 hours. Approximately 80% of patients with a BL allergy still received a BL and hypersensitivity rates were low. This study gives clinicians some evidence that using BL in patients with a BL allergy may be appropriate to treat a patient most effectively.

One of the major limitations of this study is the small sample size of aztreonam-treated patients over the 2 years, specifically for *P. aeruginosa*. Our institution implemented an antimicrobial stewardship restriction on aztreonam starting in 2015, in the middle of the retrospective study period. This meant that there needed to be permission in order to prescribe empiric aztreonam after 2015 or documentation of a severe BL allergy. This could drastically reduce the number of cases where aztreonam could still be used as an empiric therapy; additionally, authors suggest the results of this analysis be interpreted with caution due to the limited sample size. Another limitation was the lack of descriptive data toward BL allergies. The EMR system reported only whether they were allergic to penicillin with not much description, so we may have underrepresented patients with BL allergies. Finally, although necessary for independence of observations, we looked only at the first hospital stay of a patient who was readmitted multiple times within the 2 years, which may have caused some missed cases of patients treated empirically with aztreonam.

Despite these limitations, the findings of this retrospective analysis suggest that, with limitations, when using aztreonam as an empiric therapy in a patient subsequently found to have a *P. aeruginosa* infection, empiric therapy failure occurred more often than for patients treated with using a standard antipseudomonal BL. Approximately, one-third of patients within the aztreonam group had a documented BL allergy, demonstrating an inclination of clinicians to use this drug as an empiric therapy despite the availability of more appropriate therapies.

**Conclusion**

Although definitive conclusions cannot be made based on the results of this analysis, this study reinforces antimicrobial stewardship principles, including proper assessment of patients with BL allergies to promote use of first-line agents for treatment of infectious diseases. The use of aztreonam should be reserved for patients with severe BL allergies, since more appropriate alternative antimicrobial options exist that can be safely administered following evaluation and clinical confirmation of the reported allergy. Additional studies with larger sample sizes and direct comparisons to specific BL agents could support these findings. These data can be used by clinicians to aid in the choice of empiric therapy for a patient with a suspected gram-negative bacterial infection, more specifically *P. aeruginosa*, to improve clinical outcomes.

**Key points**

1. The results of this study suggest that empiric aztreonam use led to increased empiric therapy failure in patients with *P. aeruginosa* infection.
2. More than half of clinicians (61.1%) changed therapy for those patients receiving aztreonam as an empiric therapy once cultures and sensitivities were known.
3. Little more than half (55.6%) of patients who were given aztreonam empirically were considered inappropriate or were resistant to aztreonam once susceptibilities were known.
Disclosure
The authors report no conflicts of interest in this work.

References
Effectiveness of aztreonam compared to BL for *P. aeruginosa* infections